Emil Tanghetti
About
In The Last Decade
Emil Tanghetti
125 papers receiving 2.0k citations
Peers
Comparison fields: 5 of 105
- Dermatology 1.9k
- Cell Biology 470
- Epidemiology 300
- Radiology, Nuclear Medicine and Imaging 212
- Surgery 165
Countries citing papers authored by Emil Tanghetti
This map shows the geographic impact of Emil Tanghetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emil Tanghetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emil Tanghetti more than expected).
Fields of papers citing papers by Emil Tanghetti
This network shows the impact of papers produced by Emil Tanghetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emil Tanghetti. The network helps show where Emil Tanghetti may publish in the future.
Co-authorship network of co-authors of Emil Tanghetti
This figure shows the co-authorship network connecting the top 25 collaborators of Emil Tanghetti. A scholar is included among the top collaborators of Emil Tanghetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emil Tanghetti. Emil Tanghetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 1 | |
| 3 | 2 | |
| 4 | 1 | |
| 5 | 0 | |
| 6 | 1 | |
| 7 | 1 | |
| 8 | 19 | |
| 9 | 1 | |
| 10 | A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle-Controlled Clinical Study to Compare the Safety and Efficacy of a Novel Tazarotene 0.045% Lotion and Tazarotene 0.1% Cream in the Treatment of Moderate-to-Severe Acne Vulgaris | 20 |
| 11 | 5 | |
| 12 | Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. | 35 |
| 13 | A status report on topical tazarotene in the management of acne vulgaris. | 5 |
| 14 | Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. | 58 |
| 15 | Randomized comparison of the safety and efficacy of tazarotene 0.1% cream and adapalene 0.3% gel in the treatment of patients with at least moderate facial acne vulgaris. | 28 |
| 16 | 24 | |
| 17 | Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. | 14 |
| 18 | Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. | 41 |
| 19 | An observation study evaluating the treatment of plaque psoriasis with tazarotene gels, alone and with an emollient and/or corticosteroid. | 20 |
| 20 | 51 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.